| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,990,000 |
| Market
Cap: |
679.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$12.17 - $24.61 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
57,878 |
165,115 |
165,115 |
195,533 |
| Total Sell Value |
$1,217,382 |
$3,085,988 |
$3,085,988 |
$4,069,195 |
| Total People Sold |
2 |
2 |
2 |
3 |
| Total Sell Transactions |
4 |
7 |
7 |
14 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pakola Steve |
Chief Medical Officer |
• – – |
2022-01-01 |
4 |
D |
$32.70 |
$37,670 |
D/D |
(1,152) |
9,848 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2022-01-01 |
4 |
D |
$32.70 |
$118,897 |
D/D |
(3,636) |
274,048 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2021-12-31 |
4 |
A |
$27.80 |
$28 |
D/D |
1 |
19,599 |
|
- |
|
| Fox Allan M. |
|
– • – |
2021-12-23 |
4 |
S |
$34.92 |
$1,794,784 |
I/I |
(51,231) |
1,529,981 |
|
18% |
|
| Fox Allan M. |
|
– • – |
2021-12-22 |
4 |
S |
$34.40 |
$2,120,575 |
I/I |
(61,638) |
1,581,212 |
|
18% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-12-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,300 |
277,684 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-11-08 |
4 |
AS |
$40.00 |
$60,000 |
D/D |
(1,500) |
280,984 |
|
-23% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-11-08 |
4 |
OE |
$3.76 |
$5,640 |
D/D |
1,500 |
282,484 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-09-27 |
4 |
AS |
$42.19 |
$63,285 |
D/D |
(1,500) |
280,984 |
|
-39% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-09-27 |
4 |
OE |
$3.76 |
$5,640 |
D/D |
1,500 |
282,484 |
|
- |
|
| Fox Allan M. |
Director |
– • – |
2021-09-17 |
4 |
S |
$45.04 |
$2,172,323 |
I/I |
(48,233) |
1,364,309 |
|
43% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-09-14 |
4 |
AS |
$45.11 |
$1,578,850 |
D/D |
(35,000) |
280,984 |
|
-43% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-09-14 |
4 |
OE |
$0.85 |
$126,205 |
D/D |
35,000 |
315,984 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-09-13 |
4 |
AS |
$40.02 |
$120,060 |
D/D |
(3,000) |
280,984 |
|
-39% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-09-13 |
4 |
OE |
$3.76 |
$11,280 |
D/D |
3,000 |
283,984 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2021-07-27 |
4 |
OE |
$0.85 |
$8,500 |
D/D |
10,000 |
123,640 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2021-06-30 |
4 |
A |
$33.02 |
$18,327 |
D/D |
555 |
19,598 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-06-25 |
4 |
AS |
$40.25 |
$60,375 |
D/D |
(1,500) |
280,984 |
|
-10% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-06-25 |
4 |
OE |
$3.76 |
$5,640 |
D/D |
1,500 |
282,484 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-06-24 |
4 |
AS |
$40.02 |
$180,090 |
D/D |
(4,500) |
280,984 |
|
-10% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-06-24 |
4 |
OE |
$3.76 |
$16,920 |
D/D |
4,500 |
285,484 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-02-25 |
4 |
AS |
$40.77 |
$61,155 |
D/D |
(1,500) |
280,984 |
|
-6% |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2021-02-25 |
4 |
OE |
$0.85 |
$1,275 |
D/D |
1,500 |
282,484 |
|
- |
|
| Christmas Patrick J. |
Chief Legal Officer |
• – – |
2021-02-12 |
4 |
AS |
$49.08 |
$230,725 |
D/D |
(4,701) |
16,372 |
|
-14% |
|
| Christmas Patrick J. |
Chief Legal Officer |
• – – |
2021-02-12 |
4 |
OE |
$12.10 |
$56,882 |
D/D |
4,701 |
21,073 |
|
- |
|
404 Records found
|
|
Page 4 of 17 |
|
|
0.24 (1.53%) 
